[
  {
    "page_idx": 0,
    "category_type": "figure",
    "bbox_norm": [
      0.20176470588235293,
      0.09688888888888889,
      0.7994117647058824,
      0.5733333333333334
    ],
    "text": "",
    "html": "",
    "pdf": "docstructbench_llm-raw-scihub-o.O-ijc.22999.pdf_3",
    "image_path": "docstructbench_llm-raw-scihub-o.O-ijc.22999.pdf_3.pdf_0.jpg"
  },
  {
    "page_idx": 0,
    "category_type": "figure_caption",
    "bbox_norm": [
      0.09705882352941177,
      0.5835555555555556,
      0.908235294117647,
      0.7622222222222222
    ],
    "text": "FIGURE 1 – Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits B16 melanoma tumor growth in vivo. (a) Subconfluent cultures of PAE/PDGFRβ cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for 1 hr on ice (left panels). Alternatively, PAE/PDGFRβ cells were incubated for 5 min at 37°C with conditioned medium or increasing amounts of PDGF-BB (right panels). PDGFRβ phosphorylation was analyzed by PDGFRβ and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed fractions of cell lysates. (b) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle (♦), 3 µM STI571 (■), 1 µM PTK787 (▲) or 3 µM STI571 and 1 µM PTK787 (●). B16/mock (c) or B16/PDGF-BB (d) cells were inoculated subcutaneously to C57B16/J mice. When the tumor volume reached 20 mm³, mice received either p.o. gavage of vehicle (♦), 100 mg/kg/day STI571 (■), 25 mg/kg/day PTK787 (▲) or 100 mg/kg/day STI571 and 25 mg/kg/day PTK787 (○). Treatment was given for 13 days for mice bearing B16/mock tumors (c) and 8 days for mice bearing B16/PDGF-BB tumors (d). Tumor volumes, determined by palpation were followed over time. Results are presented as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by *post hoc* analysis applying the Duncan adjustment. Significance is shown for the last day of treatment: *, *p* < 0.05 compared to vehicle treatment; §, *p* < 0.05 compared to PTK787 treatment; #, *p* < 0.05 compared to STI571 treatment. (e) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STI571 (25 mg/100 mg/kg/day; lanes 4 and 5), PTK787 (25 mg/kg/day, lanes 6 and 7), STI571 (100 mg/kg/day, lanes 8 and 9) or STI571 (200 mg/kg/day, lanes 10 and 11). PDGFRβ was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFRβ and phospho-tyrosine (pTyr) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1). The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFRβ band were compared to the first vehicle-treated tumor to obtain the relative receptor phosphorylation.",
    "html": "",
    "pdf": "docstructbench_llm-raw-scihub-o.O-ijc.22999.pdf_3",
    "image_path": "docstructbench_llm-raw-scihub-o.O-ijc.22999.pdf_3.pdf_0.jpg"
  }
]